This year's American Diabetes Association conference takes place right next to San Diego's baseball stadium - and like the city's well-known Padres team, Merck and Pfizer are hoping to
Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in a deal worth up to $1 billion.
NICE has rejected Janssen’s Darzalex (daratumumab) for regular NHS funding in third line multiple myeloma, saying that gaps in clinical evidence mean cost-effectiveness data are unreliable.